CYCN · As filed with the SEC
Korsana Biosciences balance sheet, by quarter
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets (Unaudited) · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | 1,391,000 | 2,823,000 | 3,240,000 | 4,568,000 |
| Accounts receivable | 0 | 0 | 1,000,000 | 100,000 |
| Prepaid expenses | 112,000 | 255,000 | 384,000 | 386,000 |
| Other current assets | 11,000 | 11,000 | 11,000 | 11,000 |
| Total current assets | 1,514,000 | 3,089,000 | 4,635,000 | 5,065,000 |
| Property, Plant and Equipment, Net | 66,000 | 66,000 | — | — |
| Other investment | 5,350,000 | 5,350,000 | 5,350,000 | 5,350,000 |
| Total assets | 6,930,000 | 8,505,000 | 9,985,000 | 10,415,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | 1,597,000 | 457,000 | 508,000 | 480,000 |
| Accrued research and development costs | 26,000 | 148,000 | 198,000 | 46,000 |
| Accrued expenses and other current liabilities | 220,000 | 1,109,000 | 194,000 | 351,000 |
| Total current liabilities | 1,843,000 | 1,714,000 | 900,000 | 877,000 |
| Commitments and contingencies (Note 6) | 0 | 0 | 0 | 0 |
| Stockholders' equity | ||||
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at June 30, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 |
| Common stock, no par value, 400,000,000 shares authorized at June 30, 2026 and December 31, 2025; 4,330,314 and 3,925,314 shares issued at June 30, 2026 and December 31, 2025, respectively; 4,256,284 and 3,821,236 shares outstanding at June 30, 2026 and December 31, 2025, respectively | 0 | 0 | 0 | 0 |
| Paid-in capital | 281,039,000 | 280,988,000 | 280,105,000 | 279,759,000 |
| Accumulated deficit | (275,952,000) | (274,197,000) | (271,020,000) | (270,221,000) |
| Total stockholders' equity | 5,087,000 | 6,791,000 | 9,085,000 | 9,538,000 |
| Total liabilities and stockholders' equity | 6,930,000 | 8,505,000 | 9,985,000 | 10,415,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.